Market revenue in 2023 | USD 16.2 million |
Market revenue in 2030 | USD 22.1 million |
Growth rate | 4.6% (CAGR from 2023 to 2030) |
Largest segment | Malignant tumors |
Fastest growing segment | Functional Disorders |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders, Ocular Diseases |
Key market players worldwide | Elekta AB ADR, Varian, Akesis Pharmaceuticals, Huiheng Industry |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gamma knife market will help companies and investors design strategic landscapes.
Malignant tumors was the largest segment with a revenue share of 46.3% in 2023. Horizon Databook has segmented the UK gamma knife market based on malignant tumors, benign tumors, vascular disorders, functional disorders, ocular diseases covering the revenue growth of each sub-segment from 2018 to 2030.
Increase in incidence of brain tumors, rise in healthcare expenditure, and growing adoption of gamma knife therapy systems in healthcare centers are among the key factors likely to drive the UK’s market. According to NHS, approximately 11,000 people are diagnosed every year with primary brain tumor, of which, 39% undergo radiotherapy treatment, representing high demand for gamma knife radiotherapy.
In addition, NHS has undertaken various initiatives such, as the NHS Cancer Strategy, and signed numerous stereotactic radiotherapy contracts with cancer care hospitals. These measures have helped provide stereotactic radiotherapy services at lower costs across the country, benefitting nearly 6,200 patients by 2019, as compared to 2,400 patients in 2015.
This led to an increase in adoption of Gamma radiotherapy, fueling the market. The UK’s healthcare expenditure improved from USD 65 billion in 1997 to USD 269.5 billion in 2020, boosting adherence to advanced care technologies. Increase in clinical studies for extending application to other treatment areas is likely to drive the market.
Horizon Databook provides a detailed overview of country-level data and insights on the UK gamma knife market , including forecasts for subscribers. This country databook contains high-level insights into UK gamma knife market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account